Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention.

Abstract:

:Developing effective vaccines against Neisseria meningitidis serogroup B has been challenging for several reasons, including the fact that the capsular polysaccharide of N. meningitidis serogroup B is a poor antigen. Therefore, studies have focused on developing vaccines that target capsular protein meningococcal antigens using reverse vaccinology, a technique that predicts likely vaccine candidates using computational analysis of the whole bacterial genome. This has resulted in a multicomponent, recombinant, meningococcal serogroup B vaccine: 4CMenB (Bexsero(®), Novartis Vaccines & Diagnostics, NC, USA), containing four main immunogenic components: two recombinant fusion proteins (Neisseria heparin-binding antigen-GNA1030 and factor H-binding protein-GNA2091); recombinant Neisserial adhesion A; and detergent-treated outer membrane vesicles derived from the meningococcal NZ98/254 strain, where porin A 1.4 is the major immunodominant antigen. In this article, we summarize the available clinical data on 4CMenB in healthy infants, adolescents and adults, and discuss the methods available for assessing vaccine efficacy.

journal_name

Immunotherapy

journal_title

Immunotherapy

authors

Esposito S,Castellazzi L,Bosco A,Musio A,Stoddard J

doi

10.2217/imt.14.11

subject

Has Abstract

pub_date

2014-01-01 00:00:00

pages

395-408

issue

4

eissn

1750-743X

issn

1750-7448

journal_volume

6

pub_type

杂志文章,评审
  • The synergy between ionizing radiation and immunotherapy in the treatment of prostate cancer.

    abstract::There has been a surge in the use of immunotherapy for genitourinary malignancies. Immunotherapy is an established treatment for metastatic renal cell carcinoma and nonmuscle invasive bladder cancer, but its potential for treating prostate cancer (PCa) remains under investigation. Despite reported survival benefits, n...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0051

    authors: Sathianathen NJ,Krishna S,Konety BR,Griffith TS

    更新日期:2017-09-01 00:00:00

  • Immunotherapy targeting colon cancer stem cells.

    abstract::In the last 10 years, cancer stem cells have interested the scientific community because this small tumorigenic population is also associated with tumor progression in human patients and specific targeting of cancer stem cells could be a strategy to eradicate cancers currently resistant to conventional therapy. Clinic...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.10.87

    authors: Iovino F,Meraviglia S,Spina M,Orlando V,Saladino V,Dieli F,Stassi G,Todaro M

    更新日期:2011-01-01 00:00:00

  • Heat-shock proteins in diagnosis and treatment: an overview of different biochemical and immunological functions.

    abstract::Heat-shock proteins (HSPs) have been involved in different functions including chaperone activity, protein folding, apoptosis, autophagy and immunity. The HSP families have powerful effects on the stimulation of innate immune responses through Toll-like receptors and scavenger receptors. Moreover, HSP-mediated phagocy...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2018-0105

    authors: Milani A,Basirnejad M,Bolhassani A

    更新日期:2019-02-01 00:00:00

  • PLAC1 immunization does not induce infertility in mice.

    abstract:AIM:Placenta specific 1 (PLAC1) is a protein rarely expressed in normal cells, except it is important for placental development, with a possible role in the establishment of the mother-fetus interface. The gene is also highly active in a wide variety of cancers and therefore, immunization with PLAC1 peptides could poss...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0019

    authors: Liso A,Massenzio F,Stracci F

    更新日期:2017-05-01 00:00:00

  • Intestinal microbiota predicts lung cancer patients at risk of immune-related diarrhea.

    abstract:AIM:Previous studies showed that some patients after the treatment of anti-programmed cell death protein-1 (anti-PD-1) antibodies experienced immune-related diarrhea. In this study, we aim to explore the association between intestinal microbiota and immune-related diarrhea. METHODS:We obtained the fecal samples of 26 ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2018-0144

    authors: Liu T,Xiong Q,Li L,Hu Y

    更新日期:2019-04-01 00:00:00

  • Dendritic cell vaccines targeting survivin in head and neck cancer.

    abstract::Evaluation of: Turksma AW, Bontkes HJ, Ruizendaal JJ et al. Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J. Transl. Med. 11, 152-165 (2013). Survivin has been identified to be an inhibitor of apoptosis and is highly expressed in many cancers. A number o...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.13.120

    authors: Lee WT

    更新日期:2013-11-01 00:00:00

  • Immune adjuvants in early life: targeting the innate immune system to overcome impaired adaptive response.

    abstract::The neonatal phase is a transitory period characterized by an absence of memory cells, favoring a slow adaptive response prone to tolerance effects and the development of Th2-type responses. However, when appropriately stimulated, neonates may achieve an immune response comparable with adult counterparts. One strategy...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.09.38

    authors: de Brito CA,Goldoni AL,Sato MN

    更新日期:2009-09-01 00:00:00

  • MAGE-A3: an immunogenic target used in clinical practice.

    abstract::Melanoma antigen family A, 3 (MAGE-A3) is a cancer-testis antigen whose expression has been demonstrated in a wide array of malignancies including melanoma, brain, breast, lung and ovarian cancer. In addition, its ability to elicit spontaneous humoral and cellular immune responses has been shown in cancer patients. As...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.29

    authors: Esfandiary A,Ghafouri-Fard S

    更新日期:2015-01-01 00:00:00

  • Modulatory effects of bortezomib on host immune cell functions.

    abstract::Bortezomib is an inhibitor of the ubiquitin-proteasome proteolytic pathway responsible for intracellular protein turnover. Cellular proteins controlled by this pathway represent a diverse group of potential therapeutic targets, particularly in cancer cells, which exploit this proteasomal pathway to promote their growt...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.66

    authors: Pellom ST Jr,Dudimah DF,Thounaojam MC,Sayers TJ,Shanker A

    更新日期:2015-01-01 00:00:00

  • Immunotherapy of chronic myeloid leukemia: present state and future prospects.

    abstract::In spite of the considerable successes that have been achieved in the treatment of chronic myeloid leukemia (CML), cure for the disease can only be obtained by the present means in a rather small minority of patients. During the past decade, considerable progress has been made in the understanding of the immunology of...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.10.2

    authors: Vonka V

    更新日期:2010-03-01 00:00:00

  • Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

    abstract::Epstein-Barr virus-associated lymphoproliferative diseases (EBV-LPD) after hematopoietic stem cell transplantation or solid-organ transplantation remain a serious and potentially life-threatening complication. In the last decade, outcomes for EBV-LPD have significantly improved. Key to this success was the development...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.10.43

    authors: Shaffer DR,Rooney CM,Gottschalk S

    更新日期:2010-09-01 00:00:00

  • Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia.

    abstract::Therapeutic vaccination with dendritic cells (DCs) is recognized as an important experimental therapy for the treatment of minimal residual disease in acute myeloid leukemia. Many sources of leukemia-associated antigens and different methods for antigen loading of DCs have been used in an attempt to optimize anti-tumo...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.09.85

    authors: van den Ancker W,van Luijn MM,Westers TM,Bontkes HJ,Ruben JM,de Gruijl TD,Ossenkoppele GJ,van de Loosdrecht AA

    更新日期:2010-01-01 00:00:00

  • What is the role of antigen-processing mechanisms in autologous tolerogenic dendritic cell therapy in organ transplantation?

    abstract::Injection of autologous tolerogenic dendritic cells is a promising strategy to diminish the burden of harmful immunosuppression in clinical transplantation. We discuss the immunoregulatory mechanisms triggered by this approach. Tolerogenic dendritic cells have long been associated with decreased antigen-processing cap...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.40

    authors: Hill M,Segovia M,Cuturi MC

    更新日期:2011-04-01 00:00:00

  • Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy.

    abstract:AIM:Few studies have compared cluster immunotherapy and conventional administration regimens. The aim of this study was to establish the safety profile of these different regimens in patients with allergic respiratory diseases who received index-of-reactivity (IR)-standardized allergen extracts by the subcutaneous rout...

    journal_title:Immunotherapy

    pub_type: 杂志文章,多中心研究

    doi:10.2217/imt.13.133

    authors: Quiralte J,Justicia JL,Cardona V,Dávila I,Moreno E,Ruiz B,García MA

    更新日期:2013-12-01 00:00:00

  • Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy.

    abstract::Background: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has emerged as a powerful immunotherapy in relapsed or refractory B-cell acute lymphoblastic leukemia. The changes in extramedullary (EM) disease in pediatric relapsed or refractory B-cell acute lymphoblastic leukemia after CAR T-cell therapy hav...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0188

    authors: Huang J,Rong L,Wang E,Fang Y

    更新日期:2021-01-01 00:00:00

  • Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance.

    abstract::Since the discovery of the CD40-CD154 costimulatory pathway and its critical role in the adaptive immune response, there has been considerable interest in therapeutically targeting this interaction with monoclonal antibodies in transplantation. Unfortunately, initial promise in animal models gave way to disappointment...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.1

    authors: Pinelli DF,Ford ML

    更新日期:2015-01-01 00:00:00

  • Rare transformation to double hit lymphoma in Waldenstrom's macroglobulinemia.

    abstract::Waldenström macroglobulinemia (WM) is a lymphoproliferative lymphoma that is characterized by monoclonal immunoglobulin M (IgM) protein and bone marrow infiltration. Its incidence is rare and rarer still is its ability to transform to a B-cell lymphoma, particularly the aggressive diffuse large B-cell lymphoma, which ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0027

    authors: Okolo ON,Johnson AC,Yun S,Arnold SJ,Anwer F

    更新日期:2017-08-01 00:00:00

  • The split personality of NKT cells in malignancy, autoimmune and allergic disorders.

    abstract::NKT cells are a heterogeneous subset of specialized, self-reactive T cells, with innate and adaptive immune properties, which allow them to bridge innate and adaptive immunity and profoundly influence autoimmune and malignant disease outcomes. NKT cells mediate these activities through their ability to rapidly express...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.11.117

    authors: Subleski JJ,Jiang Q,Weiss JM,Wiltrout RH

    更新日期:2011-10-01 00:00:00

  • Jacalin regulates IgA production by peripheral blood mononuclear cells.

    abstract:AIMS:In IgA nephropathy, circulating immune complexes containing IgA1 are deposited on the glomerular mesangium, causing mesangial cell proliferation and acceleration of extracellular matrix production. The suppressive effect of jacalin, a galactose-binding lectin, on IgA production in vitro was determined. MATERIALS ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.12.125

    authors: Miyamoto K,Chiba T,Shinohara N,Nagata Y,Asakawa N,Kato S,Mizutani N,Murata T,Nomura S,Horiuchi T

    更新日期:2012-12-01 00:00:00

  • Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer.

    abstract::Despite novel chemotherapy treatments, pancreatic ductal adenocarcinoma (PDA) remains a lethal disease. New targeted cancer vaccines may represent a viable option for patients with PDA. The Wilms' tumor 1 (WT1) antigen is one of the most widely expressed tumor-associated antigens in various types of tumors, including ...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2016-0031

    authors: Koido S,Okamoto M,Shimodaira S,Sugiyama H

    更新日期:2016-11-01 00:00:00

  • Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma.

    abstract::Aim: Autologous hematopoietic stem cell transplantation (ASCT) is the standard-of-care curative treatment for relapsed or refractory diffuse large B-cell lymphoma (RR-DLBCL), but the relapse rate is usually high. Materials & methods: In this study, we treated 14 RR-DLBCL patients by combining ASCT and anti-CD19 chimer...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0075

    authors: Wang T,Gao L,Wang Y,Zhu W,Xu L,Wang Y,Yue W,Tang G,Chen L,Chen J,Zhang W,Yu X,Feng D,Yang J

    更新日期:2020-09-01 00:00:00

  • Conference scene: progress with promising human antibodies.

    abstract::Antibodies and antibody-based therapeutics have become big business, with annual sales over US$50 billion, accounting for >6% of worldwide pharmaceutical revenues. Ten molecules have blockbuster status (>US$1 billion), with six generating more than US$6 billion in sales. In excess of 300 products based on this rapidly...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.12.5

    authors: Larrick JW

    更新日期:2012-03-01 00:00:00

  • Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients.

    abstract::In recent years, there have been reports of immunotherapy inducing objective clinical responses in limited numbers of cancer patients. More frequently, however, clinical responses are not observed. Understanding the immunological mechanisms underlying successful immunotherapy are crucial if the field is to move forwar...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.11.62

    authors: Hardwick N,Chain B

    更新日期:2011-06-01 00:00:00

  • Modulation of antitumor immunity with histone deacetylase inhibitors.

    abstract::Histone deacetylase inhibitors possess a broad array of antitumor activities; however, their net impact on the evolving antitumor immune response is highly dependent on the inhibitors used and the histone deacetylases they target. Herein, we sequentially focus on each stage of the antitumor immune response - from dend...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2017-0134

    authors: McCaw TR,Randall TD,Forero A,Buchsbaum DJ

    更新日期:2017-12-01 00:00:00

  • New immunotherapeutic strategies for the treatment of neuroblastoma.

    abstract::The prognosis of high-risk neuroblastoma (NB) is still poor, in spite of aggressive multimodal treatment. Recently, adjuvant immunotherapy with anti-GD2 antibodies combined with IL-2 or GM-CSF has been shown to improve survival. Several other immunotherapy strategies proved efficacy in preclinical models of NB, includ...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.117

    authors: Croce M,Corrias MV,Rigo V,Ferrini S

    更新日期:2015-01-01 00:00:00

  • Absence of CD4 T-cell help provides a robust CD8 T-cell response while inducing effective memory in a preclinical model of melanoma.

    abstract::Immunotherapy strategies for cancer are focused on inducing effective and specific cytotoxic responses mediated by CD8 T cells. On the other hand, immunosuppressive mechanisms induced by the tumor, such as the generation of tumor-specific CD4(+)CD25(+)FoxP3(+) Tregs, conspire against the efficacy of immunotherapies. I...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.12.39

    authors: Muccioli M,Longstaff C,Benencia F

    更新日期:2012-05-01 00:00:00

  • The safety profile of Polyoxidonium in daily practice: results from postauthorization safety study in Slovakia.

    abstract:AIM:This study assessed the safety of Polyoxidonium® 6 mg lyophilisate for solution for injection in routine practice with a special focus on signs or symptoms of potential adverse renal effects. MATERIALS & METHODS:A local, multicenter, prospective, open-label, noninterventional, uncontrolled postauthorization safety...

    journal_title:Immunotherapy

    pub_type: 杂志文章,多中心研究

    doi:10.2217/imt-2017-0116

    authors: Pružinec P,Chirun N,Sveikata A

    更新日期:2018-02-01 00:00:00

  • Genetic modification of natural killer cells for adoptive cellular immunotherapy.

    abstract::Immunotherapy of cancer is a rapidly developing field; one such development is the manipulation and use of natural killer (NK) cells. These cells with 'killer instincts' are an attractive cell to utilize, as they are directly reactive toward tumor and could potentially activate the endogenous adaptive immune system. T...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.09.36

    authors: Pegram HJ,Kershaw MH,Darcy PK

    更新日期:2009-07-01 00:00:00

  • γδ T cells as a potential tool in colon cancer immunotherapy.

    abstract::γδ T cells are capable of recognizing tumor cells and exert potent cellular cytotoxicity against a large range of tumors, including colon cancer. However, tumors utilize numerous strategies to escape recognition or killing by patrolling γδ T cells, such a downregulation of NKG2D ligands, MICA/B and ULBPs. Therefore, t...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.59

    authors: Ramutton T,Buccheri S,Dieli F,Todaro M,Stassi G,Meraviglia S

    更新日期:2014-01-01 00:00:00

  • T-regulatory/T-helper 17: promiscuous signals and fear of commitment.

    abstract::The insight gained recently on the differentiation of naive CD4 T cells challenges the dogma that expression of canonical transcription factors and production of signature cytokines portray a commitment to a specific lineage and a point of no return. For almost two decades now, the belief has been that naive CD4 T cel...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/1750743X.1.1.27

    authors: Tartar DM,van Morlan AM,Zaghouani H

    更新日期:2009-01-01 00:00:00